Suchergebnisse

Intro -- Preface -- Contents -- Contributors -- About the Editors -- Chapter 1: The Shape of Things to Come: Emerging Applications of 3D Printing in Healthcare -- 1 3D Printing: The Next Industrial Revolution -- 1.1 3D Printing in Medicine: An Overview -- 2 Personalised Medicines -- 2.1 Dose Personalisation -- 2.2 Multi-drug Combinations -- 2.3 Tailored Release Profiles -- 2.4 Improved Patient Acceptability -- 2.5 On-demand Printing -- 3 Early Phase Drug Development -- 3.1 Pre-clinical Studies and FIH Trials -- 3.2 Motivations for Using 3DP in Early Phase Drug Development -- 3.2.1 Dose Flexibility -- 3.3 Immediate Manufacture -- 3.4 Reduced Resource Investment -- 3.5 Unique Characteristics -- 4 Conclusion -- References -- Chapter 2: 3D Printing Technologies, Implementation and Regulation: An Overview -- 1 Introduction -- 2 Classification of 3D Printing Technologies -- 2.1 Industrial Applications of 3D Printing -- 2.2 3D Printing Software -- 2.3 Binder Jet Printing -- 2.4 Vat Polymerisation -- 2.4.1 Stereolithography -- 2.5 Powder Bed Fusion -- 2.5.1 Selective Laser Sintering -- 2.6 Material Extrusion -- 2.6.1 Fused Deposition Modelling -- 2.6.2 Semisolid Extrusion -- 2.6.3 Bioprinting -- 2.7 Directed Energy Deposition -- 2.8 Sheet Lamination -- 3 3D Printing Implementation in Healthcare -- 3.1 Rapid Administration and Improved Medicine Access -- 3.2 3D Printing and Wearable Diagnostics -- 3.3 Challenges to 3D Printing Implementation -- 4 Regulatory Requirements -- 4.1 Regulatory Considerations of 3D Printing in Pharmaceutics -- 5 Conclusion -- References -- Chapter 3: Binder Jet Printing in Pharmaceutical Manufacturing -- 1 Introduction -- 2 Binder Jet Methodology -- 3 Pharmaceutical Applications of Binder Jet Printing -- 3.1 Controlled-Release Formulations -- 3.2 Rapidly Dissolving Tablets.

3D printing is forecast to revolutionise the pharmaceutical sector, changing the face of medicine development, manufacture and use. Potential applications range from pre-clinical drug development and dosage form design through to the fabrication of functionalised implants and regenerative medicine. Within clinical pharmacy practice, printing technologies may finally lead to the concept of personalised medicines becoming a reality. This volume aims to be the definitive resource for anyone thinking of developing or using 3D printing technologies in the pharmaceutical sector, with a strong focus on the translation of printing technologies to a clinical setting. This text brings together leading experts to provide extensive information on an array of 3D printing techniques, reviewing the current printing technologies in the pharmaceutical manufacturing supply chain, in particular, highlighting the state-of-the-art applications in medicine and discussing modern drug product manufacture from a regulatory perspective. This book is a highly valuable resource for a range of demographics, including academic researchers and the pharmaceutical industry, providing a comprehensive inventory detailing the current and future applications of 3D printing in pharmaceuticals. Professor Abdul Basit is a Professor of Pharmaceutics at the UCL School of Pharmacy, University College London. Abdul's research sits at the interface between pharmaceutical science and gastroenterology, forging links between basic science and clinical outcomes. His research has been translated into the design of new technologies and improved disease treatments, many of which have been commercialised. Abdul is also a serial entrepreneur and has filed multiple patents, is the recepient of several research awards and has founded 3 companies (Kuecept, Intract Pharma, FabRx). He further serves as a consultant to many pharmaceutical organisations and is on the advisory boards of scientific journals, healthcare and charitable bodies. Professor Simon Gaisford holds a Chair in Pharmaceutics and is Head of the Department of Pharmaceutics at the UCL School of Pharmacy, University College London. He has published 110 papers, 8 book chapters, 4 authored books and is the recipient of multiple research awards. His research is focused on novel technologies for manufacturing medicines, particularly using ink-jet printing and 3D printing, translating his expertise by co-founding FabRx. Simon is also an expert in the physicochemical characterisation of compounds and formulations with thermal methods and calorimetry.

The simultaneous intake of food and drugs can have a strong impact on drug release, absorption, distribution, metabolism and/or elimination and consequently, on the efficacy and safety of pharmacotherapy. As such, food-drug interactions are one of the main challenges in oral drug administration. Whereas pharmacokinetic (PK) food-drug interactions can have a variety of causes, pharmacodynamic (PD) food-drug interactions occur due to specific pharmacological interactions between a drug and particular drinks or food. In recent years, extensive efforts were made to elucidate the mechanisms that drive pharmacokinetic food-drug interactions. Their occurrence depends mainly on the properties of the drug substance, the formulation and a multitude of physiological factors. Every intake of food or drink changes the physiological conditions in the human gastrointestinal tract. Therefore, a precise understanding of how different foods and drinks affect the processes of drug absorption, distribution, metabolism and/or elimination as well as formulation performance is important in order to be able to predict and avoid such interactions. Furthermore, it must be considered that beverages such as milk, grapefruit juice and alcohol can also lead to specific food-drug interactions. In this regard, the growing use of food supplements and functional food requires urgent attention in oral pharmacotherapy. Recently, a new consortium in Understanding Gastrointestinal Absorption-related Processes (UNGAP) was established through COST, a funding organisation of the European Union supporting translational research across Europe. In this review of the UNGAP Working group "Food-Drug Interface", the different mechanisms that can lead to pharmacokinetic food-drug interactions are discussed and summarised from different expert perspectives

The simultaneous intake of food and drugs can have a strong impact on drug release, absorption, distribution, metabolism and/or elimination and consequently, on the efficacy and safety of pharmacotherapy. As such, food-drug interactions are one of the main challenges in oral drug administration. Whereas pharmacokinetic (PK) food-drug interactions can have a variety of causes, pharmacodynamic (PD) food-drug interactions occur due to specific pharmacological interactions between a drug and particular drinks or food. In recent years, extensive efforts were made to elucidate the mechanisms that drive pharmacokinetic food-drug interactions. Their occurrence depends mainly on the properties of the drug substance, the formulation and a multitude of physiological factors. Every intake of food or drink changes the physiological conditions in the human gastrointestinal tract. Therefore, a precise understanding of how different foods and drinks affect the processes of drug absorption, distribution, metabolism and/or elimination as well as formulation performance is important in order to be able to predict and avoid such interactions. Furthermore, it must be considered that beverages such as milk, grapefruit juice and alcohol can also lead to specific food-drug interactions. In this regard, the growing use of food supplements and functional food requires urgent attention in oral pharmacotherapy. Recently, a new consortium in Understanding Gastrointestinal Absorption-related Processes (UNGAP) was established through COST, a funding organisation of the European Union supporting translational research across Europe. In this review of the UNGAP Working group "Food-Drug Interface", the different mechanisms that can lead to pharmacokinetic food-drug interactions are discussed and summarised from different expert perspectives.